AstraZeneca: two new indications for Lynparza
(CercleFinance.com) - AstraZeneca announced on Thursday that the European Commission has authorised the use of its cancer drug Lynparza for two new indications.
Lynparza - which is marketed with the US company Merck - has been approved in the European Union for the treatment of castration-resistant metastatic prostate cancer in men with a BRCA1 or BRCA2 mutation.
The drug has also been approved for the first-line maintenance treatment of patients with advanced HRD-positive ovarian cancer.
AstraZeneca, which this morning unveiled quarterly results that were pretty much in line with estimates, also announced that the European Union has ratified the use of Forxiga for the treatment of chronic heart failure patients with or without type 2 diabetes.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Lynparza - which is marketed with the US company Merck - has been approved in the European Union for the treatment of castration-resistant metastatic prostate cancer in men with a BRCA1 or BRCA2 mutation.
The drug has also been approved for the first-line maintenance treatment of patients with advanced HRD-positive ovarian cancer.
AstraZeneca, which this morning unveiled quarterly results that were pretty much in line with estimates, also announced that the European Union has ratified the use of Forxiga for the treatment of chronic heart failure patients with or without type 2 diabetes.
Copyright (c) 2020 CercleFinance.com. All rights reserved.